

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Rizzieri et al.

Confirmation No.: 5735

Serial No.: 10/008,062

Group Art Unit: 1642

Filed: October 19, 2001

Examiner: Alana M. Harris

For: ANTI-TENASCIN MONOCLONAL ANTIBODY THERAPY FOR LYMPHOMA

October 5, 2004

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §1.97(c)**

Sir:

Attached is a list of documents on form PTO-1449 together with a copy of each identified document. This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(c), before final Office Action or Allowance, whichever is earlier. It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.56 and Section 609 of the MPEP.

In accordance with the requirements of 37 C.F.R. § 1.97(c)(2), a check for the \$180.00 fee specified in 37 C.F.R. § 1.17(p) is enclosed. This amount is believed to be correct. However, the Commissioner is authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

Respectfully submitted,

Shawna Cannon Lemon
Registration No. 53,888

Myers Bigel Sibley & Sajovec, P.A.
P. O. Box 37428
Raleigh, North Carolina 27627
Telephone: (919) 854-1400
Facsimile: (919) 854-1401
Customer No. 20792

CERTIFICATE OF EXPRESS MAILING

Express Mail Label No. EV 473658664 US
Date of Deposit: October 5, 2004


I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Susan E. Freedman

Date of Signature: October 5, 2004

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **1** of **1****Complete if Known**

Application Number	10/008,062
Filing Date	10/19/2001
First Named Inventor	David A. Rizzieri
Group Art Unit	1642
Examiner Name	Alana M. Harris
Attorney Docket Number	5405-252

U.S. PATENTS AND PATENT PUBLICATIONS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T
		Office	Number	Kind Code (if known)			

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	1.	Bartsch, <i>The Extracellular Matrix Molecule Tenascin-C: Expression In Vivo and Functional Characterization In Vitro</i> , Progress in Neurobiology, 49 :145-168 (1996)	
	2.	Hibino et al., <i>Tenascin Suppresses CD3-Mediated T Cell Activation</i> , Biochemical and Biophysical Research Communications, 250 :119-124 (1998)	
	3.	Latijnhouwers, et al., <i>Tenascin Expression During Wound Healing in Human Skin</i> , Journal of Pathology, 178 :30-35 (1996)	
	4.	Zhou et al., <i>Expression of wound healing and stress-related proteins in keratoconus corneas</i> , Current Eye Research, 15 (11):1124-1131 (1996)	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.